Core Insights - Harmony Biosciences Holdings, Inc. (HRMY) is currently viewed as a better value opportunity compared to Repligen (RGEN) for investors interested in Medical - Biomedical and Genetics stocks [1] Valuation Metrics - HRMY has a forward P/E ratio of 12.06, significantly lower than RGEN's forward P/E of 99.13 [5] - HRMY's PEG ratio stands at 0.51, indicating a favorable valuation relative to its expected earnings growth, while RGEN's PEG ratio is much higher at 4.76 [5] - HRMY's P/B ratio is 3.71, compared to RGEN's P/B of 4.70, suggesting HRMY is more attractively priced relative to its book value [6] Zacks Rank and Style Scores - HRMY holds a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook, while RGEN has a Zacks Rank of 3 (Hold) [3] - Based on the Style Scores system, HRMY has a Value grade of A, whereas RGEN has a Value grade of D, further supporting HRMY as the preferred choice for value investors [6]

Company Overview - Harmony Biosciences Holdings, Inc. is a Pennsylvania-based commercial stage pharmaceutical company known for marketing and selling Wakix (pitolisant) [2] Investment Insights - The company provides catalysts for investors to look out for, along with buy and sell ratings, product sales forecasts, and integrated financial statements [2] - Analysts have been covering biotech, healthcare, and pharma sectors for over 5 years, producing detailed reports on more than 1,000 companies [2] Analyst Position - The analyst has no current stock, option, or similar derivative position in any of the companies mentioned but may initiate a long position in HRMY within the next 72 hours [3]

Core Viewpoint - Harmony Biosciences Holdings, Inc. (HRMY) is experiencing solid improvement in earnings estimates, which may lead to continued short-term price momentum and an improving earnings outlook [1][2]. Estimate Revisions - The upward trend in earnings estimate revisions indicates growing analyst optimism regarding Harmony Biosciences' earnings prospects, which is expected to positively impact its stock price [2]. - For the current quarter, the earnings estimate is $0.73 per share, reflecting a +62.22% change from the previous year [4]. - The Zacks Consensus Estimate for the current quarter has increased by 5.49% over the last 30 days, with one estimate moving higher and no negative revisions [4]. - For the full year, the earnings estimate stands at $2.43 per share, representing a +14.08% change from the previous year [5]. - The consensus estimate for the current year has increased by 15.8%, with one estimate moving higher and no negative revisions [5]. Zacks Rank - The positive estimate revisions have led Harmony Biosciences to achieve a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance [6]. - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [6]. Stock Performance - Harmony Biosciences shares have increased by 8.3% over the past four weeks, suggesting investor confidence in its earnings growth prospects [7].

Group 1 - Harmony Biosciences Holdings, Inc. (HRMY) shares have increased by 8.3% over the past four weeks, closing at $36.42, with a mean price target of $50.80 indicating a potential upside of 39.5% [1] - The mean estimate consists of 10 short-term price targets with a standard deviation of $13.43, where the lowest estimate is $28 (23.1% decline) and the highest is $75 (105.9% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 15.8% over the last 30 days [9][10] Group 2 - HRMY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] - The clustering of price targets with a low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [7] - While price targets may not be reliable indicators of actual price movements, they can provide a directional guide for potential stock performance [12]

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positiv ...

Company Participation in Industry Events - Harmony Biosciences Holdings Inc will participate in the 43rd Annual J P Morgan Healthcare Conference in San Francisco CA on January 15 2025 [1] - Jeffrey M Dayno MD President and Chief Executive Officer is scheduled to present at the conference at 11:15 am PT 2:15 pm ET [1] - A webcast of the fireside chat will be available on the investor page of Harmony's website [1] Company Overview - Harmony Biosciences is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare neurological diseases [2] - The company is driven by novel science visionary thinking and a commitment to addressing unmet medical needs [2] - Established by Paragon Biosciences LLC in 2017 and headquartered in Plymouth Meeting PA [2] - The company aims to create a better future through therapeutic innovations culture and community programs [2] Contact Information - Investor contact Brennan Doyle can be reached at 484-539-9700 or via email [3] - Media contact Cate McCanless can be reached at 202-641-6086 or via email [3]

Core Viewpoint - Harmony Biosciences Holdings, Inc. has announced a public offering of 8,000,000 shares of its common stock at a price of $31.00 per share, with an additional option for underwriters to purchase 1,200,000 shares [1] Group 1: Offering Details - The offering is being conducted by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC, with J.P. Morgan acting as the sole book-running manager [1] - The company will not receive any proceeds from the sale of shares, as the offering is solely from selling shareholders [1] - The offering is expected to close on November 1, 2024, subject to customary closing conditions [1] Group 2: Regulatory Information - The shares are being offered under an effective shelf registration statement filed with the SEC, and the offering is made only by means of a prospectus supplement and accompanying base prospectus [2] - Preliminary and final prospectus supplements can be obtained free of charge on the SEC's website [2] Group 3: Company Overview - Harmony Biosciences is a pharmaceutical company focused on developing therapies for rare neurological diseases with unmet medical needs [4] - Established in 2017 and headquartered in Plymouth Meeting, PA, the company emphasizes innovation and empathy in its therapeutic advancements [4]

Core Viewpoint - Harmony Biosciences Holdings, Inc. has announced a public offering of up to 8,000,000 shares of its common stock, with no proceeds going to the company itself [1] Group 1: Offering Details - The public offering is being conducted by Marshman Fund Trust II and Valor IV Pharma Holdings, LLC as the selling shareholders [1] - The selling shareholders plan to grant underwriters a 30-day option to purchase an additional 1,200,000 shares at the public offering price [1] - J.P. Morgan is acting as the sole book-running manager for the offering [2] Group 2: Regulatory Information - The shares are being offered under an effective shelf registration statement filed with the SEC, and the offering will be made via a prospectus supplement and accompanying base prospectus [3] - Copies of the preliminary prospectus supplement and base prospectus can be obtained for free on the SEC's website or through J.P. Morgan Securities LLC [3] Group 3: Company Overview - Harmony Biosciences is a pharmaceutical company focused on developing therapies for patients with rare neurological diseases [5] - The company was established in 2017 by Paragon Biosciences, LLC, and is headquartered in Plymouth Meeting, Pennsylvania [5] - The company's mission emphasizes innovation and empathy to improve the lives of patients with unmet medical needs [5]

C IF N Q3 2024 Financial Results and Business Updates October 29, 2024 Copyright © 2024 Harmony Biosciences. All rights reserved. Forward-Looking Statements This presentation includes forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strat ...

Financial Data and Key Metrics Changes - Harmony reported net revenues of $186 million for Q3 2024, an increase from $160.3 million in the same quarter of the previous year, reflecting strong underlying demand for WAKIX [28][73] - Non-GAAP adjusted net income for Q3 2024 was $59.6 million or $1.03 per diluted share, compared to $58.8 million or $0.97 per diluted share in the prior year quarter [74] - The company ended Q3 with $504.7 million in cash, cash equivalents, and investments, reflecting strong cash generation of $70.5 million from operations [75] Business Line Data and Key Metrics Changes - WAKIX net revenue for Q3 2024 was $186 million, surpassing $2 billion in cumulative net revenue since its launch [28][32] - The average number of patients on WAKIX increased to approximately 6,800, with a sequential increase of about 250 patients from the previous quarter [34] - The prescriber base for WAKIX grew, with over 40% penetration among approximately 5,000 healthcare professionals [37] Market Data and Key Metrics Changes - The growth in WAKIX was attributed mainly to the adult narcolepsy patient base, with contributions from the pediatric narcolepsy indication launch [35] - Approximately 60% of new patients came from oxybate REMS enrolled healthcare professionals, while 40% came from non-oxybate prescribers [103] Company Strategy and Development Direction - Harmony aims to become a leading CNS company focused on innovative treatments for patients with unmet medical needs, with a robust late-stage pipeline expected to deliver new product launches each year for the next five years [6][7] - The company is preparing to submit an sNDA for pitolisant in idiopathic hypersomnia and is advancing next-gen formulations of pitolisant [10][17] - Harmony's pipeline includes three orphan rare CNS franchises, with peak sales potential of $1 billion to $2 billion for each franchise [8][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 2024 net revenue guidance of $700 million to $720 million, highlighting the potential for WAKIX to exceed $1 billion in sales in the adult narcolepsy market [29][76] - The company remains focused on executing its strategy while advancing its late-stage development programs [72][31] Other Important Information - Harmony has approximately $505 million in cash, providing financial flexibility for further business development opportunities [30] - The company is committed to addressing serious unmet medical needs in rare neurological diseases, with a focus on delivering innovative treatments [31][77] Q&A Session Summary Question: Can you provide insight on the coexistence strategy for WAKIX and the upcoming GR and HD products? - Management indicated that WAKIX will remain the foundational business, with GR expected to expand the patient base without converting existing WAKIX patients. HD is anticipated to attract a majority of current WAKIX patients due to its enhanced efficacy [80][84] Question: What is the status of the orexin program and when will additional data be presented? - Management confirmed that additional preclinical data on the orexin receptor agonist will be shared at upcoming scientific meetings, with a target for next year [86][88] Question: How does EPX-100 differentiate itself from competitors in terms of safety and clinical development? - Management highlighted EPX-100's established safety profile, its BID dosing regimen, and its advanced stage in clinical development compared to other investigational products [90][92]